France's Innate Pharma posts lower 2025 revenue as key contracts decline

Innate Pharma SA

26/03/2026 06:11

Corrects Key Details table to show FY Operating Expenses were positive, not negative

Overview

France immunotherapy developer's 2025 revenue and other income fell 55% yr/yr

Net loss for 2025 was little changed at €49.2 mln

Company implementing layoffs under redundancy plan, completion expected in H1 2026

Outlook

Company anticipates cash runway until end of Q3 2026

Innate Pharma plans to initiate TELLOMAK-3 Phase 3 trial in H2 2026, pending financing

PACIFIC-9 Phase 3 trial data readout expected in H2 2026

Result Drivers

COLLABORATION REVENUE DROP - Revenue from collaboration and licensing agreements fell sharply as key contracts with AstraZeneca and Sanofi were completed or discontinued

LOWER R&D COSTS - Operating expenses declined mainly due to reduced direct research and development costs related to clinical programs and lower personnel and consulting expenses

RESTRUCTURING CHARGES - Company incurred restructuring charges as part of workforce reduction plan implemented in 2025

Company press release: ID:nBw2117qMa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Adjusted Operating Income
-EUR 54.008 mln
FY Basic EPS
-EUR 0.55
FY EPS continuing operations
-EUR 0.55
FY Net Income continuing operations
-EUR 49.18 mln
FY Operating Expenses
EUR 63.01 mln
FY Operating Income
-EUR 54.008 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)